Active Ingredient History
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. The exact mechanism of action of fluvoxamine has not been fully determined, but appears to be linked to its inhibition of CNS neuronal uptake of serotonin. Fluvoxamine blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. In-vitro studies suggest that fluvoxamine is more potent than clomipramine, fluoxetine, and desipramine as a serotonin-reuptake inhibitor. Studies have also demonstrated that fluvoxamine has virtually no affinity for α1- or α2-adrenergic, β-adrenergic, muscarinic, dopamine D2, histamine H1, GABA-benzodiazepine, opiate, 5-HT1, or 5-HT2 receptors. Fluvoxamine is used for management of depression and for Obsessive Compulsive Disorder (OCD). Has also been used in the management of bulimia nervosa. Fluvoxamine is known under the brand names: Faverin, Fevarin, Floxyfral, Dumyrox and Luvox. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Obsessive-Compulsive Disorder (approved 2007)
Anxiety Disorders (Phase 4)
Anxiety, Separation (Phase 3)
Autistic Disorder (Phase 3)
Breast Neoplasms (Phase 1)
Coronavirus (Phase 3)
Coronavirus Infections (Phase 2)
COVID-19 (Phase 3)
Dementia (Phase 3)
Depression (Phase 4)
Depressive Disorder, Major (Phase 4)
Dermatitis, Atopic (Phase 1)
Drug Interactions (Phase 1)
Fatigue Syndrome, Chronic (Phase 3)
Healthy Volunteers (Phase 1)
Mental Disorders (Phase 4)
Non-alcoholic Fatty Liver Disease (Phase 1)
Obsessive Behavior (Phase 4)
Obsessive-Compulsive Disorder (Phase 4)
Olfaction Disorders (Phase 2)
Olfactory Nerve Diseases (Phase 2)
Pharmacokinetics (Phase 1)
Pharmacology, Clinical (Phase 1)
Phobia, Social (Phase 3)
Psychophysiologic Disorders (Phase 3)
SARS-CoV-2 (Phase 2)
Schizophrenia (Phase 4)
Treatment Outcome (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
